{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-127517","form_type":"8-K","ticker":null,"cik":"0001772028","company_name":"Scopus BioPharma Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.056976+00:00","generated_at":"2026-06-21T03:28:29.980474+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Scopus BioPharma receives Nasdaq delisting notice; trading suspended Dec 19","bullets":["Nasdaq Panel determined to delist SCPS after company failed to meet compliance milestones, including a specified financing transaction.","Nasdaq trading will be suspended effective at the open on December 19, 2022.","Company expects to trade on OTC Markets under same ticker SCPS; has applied for the OTCQB Venture Market.","No assurance OTCQB application will be approved or that company can satisfy ongoing reporting requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-127517","json":"https://secwatch.observer/filing/0001104659-22-127517.json","markdown":"https://secwatch.observer/filing/0001104659-22-127517.md","text":"https://secwatch.observer/filing/0001104659-22-127517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1772028/000110465922127517/0001104659-22-127517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1772028/000110465922127517/tm2232869d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:28:29.980474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f9c4308549689ac2cbac0f73f32bbe0aaab613f","claim":"Scopus BioPharma Inc. received a nasdaq delisting notice notice.","evidence_excerpt":"December 15, 2022, of its determination to delist the Company’s common stock from Nasdaq. Such letter further informed the Company that Nasdaq will complete the delisting after, among other things, the lapsing of applicable appeal periods and that trading of the Company’s common stock on Nasdaq will be suspended effective at the open of trading on December 19, 2022. The Company anticipates that, upon suspension of trading on Nasdaq, its common stock will commence trading on one of the markets operated by the OTC Markets Group under its existing ticker symbol “SCPS”. The Company has submitted a","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1772028/000110465922127517/0001104659-22-127517-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}